Navigation Links
GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
Date:9/8/2009

NEW YORK, NY, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Anders Boegh Jensen to its Scientific Advisory Board (SAB).

Dr. Boegh Jensen will contribute his considerable expertise in biotechnology and molecular biology to GENova's business of identifying, evaluating and developing pioneering research drugs. His expertise is acknowledged by companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.

Aaron Whiteman, CEO of GENova, says, "We are delighted to have Mr. Boegh Jensen join the SAB. His credentials and experience in the biotech field will be an asset to GENova as we continue to identify promising cancer-fighting drug patents."

Anders Boegh Jensen, Ph.D.

Anders Boegh Jensen is a biochemist who specializes in biotechnology, genetics and molecular biology. He is currently the Director at Poalis, a plant-based biotechnology company, and serves as an Industrial Representative Board Member at the Danish Society for Biochemistry and Molecular Biology. Dr. Boegh Jensen is also frequently published in leading industry journals such as "Cell". His previous position was Associate Professor at the Institute of Molecular Biology at the University of Copenhagen where he helped modernize biology education and developed advanced Ph.D. courses.

Anders Boegh Jensen's academic credentials include: completion of a Master's thesis at the Institute of Molecular Biology, University of Copenhagen in 1989; a one-year research term at the Carlsberg Research Laboratory; and being awarded a four-year European Union BRIDGE mobility fellowship for his post-graduate research training at the Dept. of Plant Molecular Genetics, CID, CSIC, Barcelona, Spain. He completed his Ph.D thesis in Molecular Biology and Genetics in 1994.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genova files patent for new prostate cancer treatment
2. GENova names Dr. John Savin as Vice President
3. GENova names Aaron Whiteman as CEO
4. Allscripts to Announce Fiscal First Quarter Results on September 29, 2009; Company Appoints Vice President of Investor Relations
5. KV Pharmaceutical Appoints Interim Chief Financial Officer
6. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
7. Mindray DS USA Appoints Michael Thompson Vice President of U.S. Ultrasound Sales
8. XLHealth Appoints New Controller to Lead Financial Compliance, Accounting Initiatives
9. IMIA Interpreter Association Appoints Brazil Representative
10. HCA Appoints Dr. Richard Tayrien Chief Health Information Officer
11. SCOLR Pharma, Inc. Appoints Stephen J. Turner as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of ... up with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week ... Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using ... Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          ... boosting quality. , It’s known as the “CY2016 Annual FDA Medical Device Quality ...
(Date:7/20/2017)... ... 2017 , ... The Business Architecture Guild® is pleases to ... )v 6.0 is now available for member download. This release is dedicated to ... Non-members may download the Part 1 Introduction for free at http://www.businessarchitectureguild.org. ...
(Date:7/20/2017)... ... July 19, 2017 , ... A local summer ... increased funds raised to support fine arts programs in Chester County’s Elementary Schools. ... Freed-Hardeman University’s Loyd Auditorium. , More than 850 people attended the two ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... million Health Resources and Services Administration (HRSA) grant to train predoctoral dental students ... care needs in rural and underserved areas. , The Predoctoral Pediatric Training Project ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology: